EUROFINS SCIENT Income After Taxes 2018-2024 | ERFSF
EUROFINS SCIENT annual/quarterly income after taxes history and growth rate from 2018 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
- EUROFINS SCIENT income after taxes for the quarter ending June 30, 2024 was $0M, a 0% increase year-over-year.
- EUROFINS SCIENT income after taxes for the twelve months ending June 30, 2024 was $0M, a 0% increase year-over-year.
- EUROFINS SCIENT annual income after taxes for 2023 was $0.333B, a 47.81% decline from 2022.
- EUROFINS SCIENT annual income after taxes for 2022 was $0.638B, a 31.1% decline from 2021.
- EUROFINS SCIENT annual income after taxes for 2021 was $0.926B, a 50.04% increase from 2020.
| EUROFINS SCIENT Annual Income After Taxes (Millions of US $) |
|
|---|---|
| 2023 | $333 |
| 2022 | $638 |
| 2021 | $926 |
| 2020 | $617 |
| 2019 | $219 |
| 2018 | $264 |
| 2017 | $247 |
| 2016 | $2,762 |
| 2015 | $0 |
| EUROFINS SCIENT Quarterly Income After Taxes (Millions of US $) |
|
|---|---|
| 2024-06-30 | |
| 2023-06-30 | |
| 2022-12-31 | |
| 2021-12-31 | |
| 2021-06-30 | |
| 2020-12-31 | |
| 2020-06-30 | |
| 2019-12-31 | |
| 2019-06-30 | |
| 2018-12-31 | |
| 2018-06-30 | |
| 2017-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.447B | $7.522B |
| Eurofins Scientific SE provides testing services. The company provides food and feed testing, bioanalytical, biopharma, pharma discovery, pharma early development, pharma central laboratory, biopharma product testing, genomic, agroscience, consumer product testing, forensic, environment testing and REACH services. It operates primarily in Benelux, France, Germany, North America, Nordic countries, the United Kingdom, Ireland and internationally. Eurofins Scientific SE is headquartered in Luxembourg. | |||